OTCMKTS:AGNPF

Algernon Pharmaceuticals Stock Forecast, Price & News

$3.18

-0.21 (-6.19%)

(As of 12/3/2021 12:00 AM ET)

Add

Compare

Today's Range: $3.04
▼
$3.47
50-Day Range: $0.04
▼
$7.20
52-Week Range: $0.03
▼
$0.44

Volume: 6,821 shs
Average Volume: 492,228 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive AGNPF News and Ratings via Email

Sign-up to receive the latest news and ratings for Algernon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Algernon Pharmaceuticals

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonÂ-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188 (N,N-Dimethyltryptamine), a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial
December 2, 2021 | finance.yahoo.com

Algernon Pharmaceuticals appoints former Medicure financial chief James Kinley as CFO
November 30, 2021 | proactiveinvestors.com

Algernon Pharmaceuticals Announces New Chief Financial Officer
November 30, 2021 | finance.yahoo.com

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest Up 1,175.0% in November
November 27, 2021 | americanbankingnews.com

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
November 24, 2021 | finance.yahoo.com

Algernon Pharmaceuticals Stock Set to Reverse Split on Wednesday, November 24th (OTCMKTS:AGNPF)
November 20, 2021 | americanbankingnews.com

Algernon Pharmaceuticals Announces Share Consolidation
November 17, 2021 | finance.yahoo.com

Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Expands By 200.0%
November 16, 2021 | americanbankingnews.com

The Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest News
November 1, 2021 | finance.yahoo.com

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
November 1, 2021 | finance.yahoo.com

Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
October 26, 2021 | finance.yahoo.com

Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market
October 21, 2021 | finance.yahoo.com

The Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News
October 15, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:AGNPF
Previous Symbol
CUSIP: N/A
CIK: 1642178
Web: algernonpharmaceuticals.com
Phone: N/A
Fax: N/A
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Algernon Pharmaceuticals.

0.0 Community Rank

Outperform Votes
Algernon Pharmaceuticals has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Algernon Pharmaceuticals has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Algernon Pharmaceuticals and other stocks. Vote “Outperform” if you believe AGNPF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGNPF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Algernon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Algernon Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Algernon Pharmaceuticals insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Algernon Pharmaceuticals (OTCMKTS:AGNPF) Frequently Asked Questions

Are investors shorting Algernon Pharmaceuticals?: Algernon Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 15,300 shares, an increase of 1,175.0% from the October 31st total of 1,200 shares. Based on an average daily trading volume, of 639,500 shares, the short-interest ratio is currently 0.0 days.
View Algernon Pharmaceuticals' Short Interest.
When did Algernon Pharmaceuticals' stock split? How did Algernon Pharmaceuticals' stock split work?: Algernon Pharmaceuticals's stock reverse split on the morning of Wednesday, November 24th 2021. The 1-100 reverse split was announced on Wednesday, November 24th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 24th 2021. An investor that had 100 shares of Algernon Pharmaceuticals stock prior to the reverse split would have 1 shares after the split.
Who are Algernon Pharmaceuticals' key executives?: Algernon Pharmaceuticals' management team includes the following people:
Mr. Christopher J. Moreau, CEO & Director (Age 55, Pay $212.8k)
Mr. Michael S. M. Sadhra CA, CPA, CFO & Director (Age 52, Pay $66.24k)
Dr. Christopher Bryan Ph.D., VP of Research & Operations
Dr. Ahmad Khalil, Chief Medical Officer
Who are some of Algernon Pharmaceuticals' key competitors?: Some companies that are related to Algernon Pharmaceuticals include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), ALK-Abello A/S (AKBLF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of AGNPF's competitors.
What is Algernon Pharmaceuticals' stock symbol?: Algernon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AGNPF."
How do I buy shares of Algernon Pharmaceuticals?: Shares of AGNPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Algernon Pharmaceuticals' stock price today?: One share of AGNPF stock can currently be purchased for approximately $3.18.
What is Algernon Pharmaceuticals' official website?: The official website for Algernon Pharmaceuticals is algernonpharmaceuticals.com.
Where are Algernon Pharmaceuticals' headquarters?: Algernon Pharmaceuticals is headquartered at 700 West Pender Street, Vancouver, BC V6C.

This page was last updated on 12/5/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.